Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke
Jung-Hee Ha, Dong‐Woo Choi, Kwang Joon Kim, et al.
Neurology (2023) Vol. 100, Iss. 17
Open Access | Times Cited: 21

Showing 21 citing articles:

Focusing on mitochondria in the brain: from biology to therapeutics
Nanshan Song, Shuyuan Mei, Xiang-Xu Wang, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 12
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Hae‐Kyung Kim, Geert Jan Biessels, Min Yu, et al.
Neurology (2024) Vol. 103, Iss. 8
Closed Access | Times Cited: 12
Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications
Mateusz Kciuk, Weronika Kruczkowska, Julia Gałęziewska, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 11955-11955
Open Access | Times Cited: 8
Vascular cognitive impairment and dementia: Mechanisms, treatment, and future directions
Vincent Mok, Cai Yuan, Hugh S Markus
International Journal of Stroke (2024) Vol. 19, Iss. 8, pp. 838-856
Closed Access | Times Cited: 7
Current and Future Treatments of Vascular Cognitive Impairment
Bonaventure Ip, Ho Ko, Bonnie Yin Ka Lam, et al.
Stroke (2024) Vol. 55, Iss. 4, pp. 822-839
Closed Access | Times Cited: 7
Therapeutic Potential and Challenges of Pioglitazone in Cancer Treatment
Maria Vasileiou, Sotirios Charalampos Diamantoudis, Christina Tsianava, et al.
Applied Sciences (2025) Vol. 15, Iss. 4, pp. 1925-1925
Open Access
Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases
Germán Plascencia‐Villa, George Perry
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12486-12486
Open Access | Times Cited: 10
Qingxin Kaiqiao Fang decreases Tau hyperphosphorylation in Alzheimer's disease via the PI3K/Akt/GSK3β pathway in vitro and in vivo
Shuo Liu, Luting Xu, Yan Shen, et al.
Journal of Ethnopharmacology (2023) Vol. 318, pp. 117031-117031
Open Access | Times Cited: 9
Alzheimer’s Disease, Obesity, and Type 2 Diabetes: Focus on Common Neuroglial Dysfunctions (Critical Review and New Data on Human Brain and Models)
A. Tolédano, Arantxa Rodríguez‐Casado, María‐Isabel Álvarez, et al.
Brain Sciences (2024) Vol. 14, Iss. 11, pp. 1101-1101
Open Access | Times Cited: 3
Protective effects of pioglitazone in renal ischemia–reperfusion injury (RIRI): focus on oxidative stress and inflammation
Maryam Golmohammadi, Mehraveh Sadeghi Ivraghi, Ekhlas Khammas Hasan, et al.
Clinical and Experimental Nephrology (2024) Vol. 28, Iss. 10, pp. 955-968
Closed Access | Times Cited: 2
Anti-diabetics and the Prevention of Dementia: A Systematic Review
Ethan Slouha, Fadi Ibrahim, Atbeen Rezazadah, et al.
Cureus (2023)
Open Access | Times Cited: 5
The segmented flavivirus Alongshan virus reduces mitochondrial mass via degrading STAT2 to suppress innate immune response
Yinghua Zhao, Liyan Sui, Mingming Pan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Effects of antidiabetic agents on platelet characteristics with implications in Alzheimer's disease: Mendelian randomization and colocalization study
Zhipeng Xie, Yijie Liu, Min Huang, et al.
Heliyon (2024) Vol. 10, Iss. 10, pp. e30909-e30909
Open Access | Times Cited: 1
The segmented flavivirus Alongshan virus reduces mitochondrial mass by degrading STAT2 to suppress the innate immune response
Y. Zhao, Liyan Sui, Mingming Pan, et al.
Journal of Virology (2024) Vol. 99, Iss. 1
Open Access | Times Cited: 1
What is the role of pioglitazone for patients with type 2 diabetes in value-based care settings?
Andrea Bush, Tina Benny, Genevieve M Hale, et al.
Drugs & Therapy Perspectives (2024) Vol. 40, Iss. 3, pp. 131-136
Closed Access
Drug Repurposing in CNS Disorders
Nazir Hussain, Snigdha Singh, Amit Alexander
Drug repurposing (2024), pp. 109-133
Closed Access
Impact of diabetes on the progression of Alzheimer’s disease via trajectories of amyloid–tau–neurodegeneration (ATN) biomarkers
Eun Woo Kim, Keun You Kim, Eosu Kim
The journal of nutrition health & aging (2024) Vol. 29, Iss. 2, pp. 100444-100444
Open Access
Chronic Kidney Disease in Patients with Hip Fracture: Prevalence and Outcomes
Alexander A. Fisher, Jo-Wai Douglas Wang, Paul N. Smith
International Journal of Clinical Practice (2024) Vol. 2024, pp. 1-26
Open Access
Pioglitazone and Lower Risk of Dementia
Colleen J. Maxwell, Wajd Alkabbani, Sevil Yaşar
Neurology (2023) Vol. 100, Iss. 17, pp. 803-804
Closed Access | Times Cited: 1
Reader Response: Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke
Feng Qian
Neurology (2023) Vol. 100, Iss. 24, pp. 1166-1166
Open Access
Paradigmenwechsel in der Diabetologie
Johanna Zielinski
Ernährung & Medizin (2023) Vol. 38, Iss. 03, pp. 131-135
Closed Access
Page 1

Scroll to top